Publication: Impact of systemic inflammatory markers in patients with alk -positive non-small cell lung cancer treated with crizotinib
dc.contributor.author | Ölmez, O. F. | |
dc.contributor.author | Bilici, A. | |
dc.contributor.author | Gürsoy, P. | |
dc.contributor.author | Sakin, A. | |
dc.contributor.author | Korkmaz, T. | |
dc.contributor.author | Çil, I. | |
dc.contributor.author | Çakar, B. | |
dc.contributor.author | Menekse, S. | |
dc.contributor.author | Demir, T. | |
dc.contributor.author | Acıkgöz, O. | |
dc.contributor.author | Hamdard, J. | |
dc.contributor.buuauthor | Çubukcu, Erdem | |
dc.contributor.buuauthor | ÇUBUKÇU, ERDEM | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı. | |
dc.date.accessioned | 2024-10-08T05:16:58Z | |
dc.date.available | 2024-10-08T05:16:58Z | |
dc.date.issued | 2023-11-01 | |
dc.description.abstract | Objectives: To evaluate the prognostic utility of inflammation-based prognostic scores in patients with ALK-positive metastatic or non-resectable non-small-cell lung cancer (NSCLC) treated with crizotinib.Patients and Methods: A total of 82 patients with ALK-positive metastatic or non-resectable NSCLC who received ALK TKI crizotinib were included. Pre-treatment modified Glasgow prognostic score (mGPS), prognostic nutritional index (PNI), and systemic immune-inflammation index (SII) were calculated. Multivariable logistic regression and Cox proportional hazards models were used to assess the impact of pretreatment mGPS, PNI, and SII on overall survival (OS), progression-free survival (PFS), and objective response rate (ORR).Results: The ORR was 77.2%, while 1-year OS and PFS rates were 95.0% and 93.5%, respectively. The univariate analysis revealed significantly higher 1-year PFS (89.4 vs. 64.4%, p=0.043) and OS (92.0 vs. 83.3%, p=0.01) rates in patients with low (<934.7) vs. high (>= 934.7) SII scores. Multivariate analysis revealed that PNI >= 0.09 was a significant determinant of poorer 1-year OS rates (hazard ratio [HR]: 2.46, 95% confidence interval [CI] 0.88-4.85, p=0.035). No significant difference was observed in survival rates according to gender, age, smoking status, prior lines of therapy, or mGPS scores, while higher mGPS scores (odds ratio [OR]: 0.1, 95%CI 0.16-1.04; p=0.009) and higher PNI scores (OR: 0.16, 95% CI 0.02-0.55; p=0.035) were associated with poorer ORR.Conclusion: Our findings indicate the prognostic significance of PNI and SII in terms of survival outcome and the impact of mGPS and PNI on treatment response in patients with ALK-positive NSCLC treated with crizotinib. | |
dc.identifier.doi | 10.1016/j.pulmoe.2022.11.006 | |
dc.identifier.endpage | 485 | |
dc.identifier.issn | 2531-0437 | |
dc.identifier.issue | 6 | |
dc.identifier.startpage | 478 | |
dc.identifier.uri | https://doi.org/10.1016/j.pulmoe.2022.11.006 | |
dc.identifier.uri | https://hdl.handle.net/11452/46011 | |
dc.identifier.volume | 29 | |
dc.identifier.wos | 001110055900001 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Elsevier | |
dc.relation.journal | Pulmonology | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.subject | Prognostic nutritional index | |
dc.subject | Predicting prognosis | |
dc.subject | Lymphocyte ratio | |
dc.subject | Stage-i | |
dc.subject | Chemotherapy | |
dc.subject | Survival | |
dc.subject | Progression | |
dc.subject | Docetaxel | |
dc.subject | Outcomes | |
dc.subject | Scores | |
dc.subject | Nsclc | |
dc.subject | Alk-positive | |
dc.subject | Inflammation-based prognostic scores | |
dc.subject | Treatment response | |
dc.subject | Survival | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Respiratory system | |
dc.title | Impact of systemic inflammatory markers in patients with alk -positive non-small cell lung cancer treated with crizotinib | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | f971677f-09c5-4463-bf01-3c6341fbe5f7 | |
relation.isAuthorOfPublication.latestForDiscovery | f971677f-09c5-4463-bf01-3c6341fbe5f7 |